Assembly biosciences reports positive topline results from phase 1b clinical trial of next-generation investigational capsid assembly modulator abi-4334 in chronic hepatitis b

– favorable safety and tolerability profile, as well as pharmacokinetics supporting once-daily oral dosing, continued to be observed in final 400 mg cohort –

ASMB Ratings Summary

ASMB Quant Ranking